Go to the USUHS home page

  Our products
  A to Z index
  Contact us

Biodosimetry Tools

Emergency Response Resources
  Advisory team
  Other resources

Managing Radiation Casualties
  Depleted uranium
  Potassium iodide
  Prussian blue
  Radiation patient treatment
  Managing radiological casualties
  Response to nuclear detonation
      • 1st Edition (Jan 2009)
      • 2nd Edition (Jun 2010)
  NCRP recommendations
  Consequences of nuclear warfare

Medical Effects of Ionizing Radiation
  In-person course
  Online course
  Schedule, fees, registration
  Course resources
  » What is ionizing radiation? «
  » Veterans' radiation exposure «

Product Quick List
  Exposure assessment tools

  Books/book chapters
  Contract reports
  Journal articles/supplements
  Reports/report chapters
  Scientific reports
  Special publications
  Technical reports

Register AFRRI Products

Research Programs
  Combined Injury: Radiation with
      Other Insults

  Internal Contamination and
      Metal Toxicity

  Countermeasure Development

2014 AFRRI Seminars

USU Dept. of Radiation Biology
You are here:  HOME  >  Research Programs

Research Programs

Jump to:  Research areas | Representative publications: Biodosimetry, Countermeasure Development, Internal Contamination and Metal Toxicity, Combined Injury: Radiation with Other Insults | Graduate education in Radiation Biology | Seminars
The military services look to the Armed Forces Radiobiology Research Institute for developments that will preserve the health and performance of our forces in the face of extraordinary threats on and off the battlefield. The investment in the human factor that AFRRI represents is vital to the national defense effort and also provides substantial benefits to humanity in general. AFRRI missions include the following:
  • Focus on the customer—Through a broad-based, customer-oriented program, the Institute maintains the research program essential to the development of applications that meet the ever-changing needs of the military services. AFRRI addresses the services' requirements simultaneously from three perspectives: prevention of health hazards, assessment of biological damage, and treatment of injuries resulting from exposure to ionizing radiation alone or in combination with chemical or biological agents encountered on the battlefield.
  • Military relevance—Advances in radioprotection strategies enable military forces to operate, when required, in nuclear or radioactive combat environments while minimizing both long- and short-term risks of the consequences of exposure to ionizing radiation. Accurate casualty prediction models promote effective command decisions and force structure planning. Advanced biological dosimetry methodology is used in triage, treatment decisions, and risk assessment. Together, the results of the three research thrusts improve therapeutic strategies for the treatment and prevention of early and long-term health effects and mitigate the risks to our personnel and their offspring.
  • Unique contributions—In addition, AFRRI provides specialized expertise to evaluate and model radiological insults combined with other battlefield insults such as infection, disease, and biological warfare and chemical warfare agents. AFRRI acts as the catalyst, in collaborations with the worldwide scientific community, to publish medical and technical information based on data from nuclear accidents or incidents in other countries, including those in states of the former Soviet Union.
  • Civilian applications—Humanity in general benefits from research and development in these areas; such developments are applicable to rescue operations involving, for example, terrorist actions or industrial nuclear accidents. The core competence in radiation biophysics and the technical database developed from AFRRI research are also applicable to astronauts exposed to space radiation.
Research areas
AFRRI research focuses on methods to prevent, assess, and treat injuries resulting from the effects of ionizing radiation.
  • Countermeasure Development—With an understanding of the mechanisms of radiation damage, AFRRI scientists are pursuing new and improved pharmacological approaches to prevent the life-threatening and health-degrading effects of ionizing radiation. Using novel cellular and molecular approaches and animal models, they move these potentially life-saving drugs from discovery through the Food and Drug Administration approval process.
  • Assessing the risks—Accurate casualty prediction models promote effective command decisions and force structure planning. AFRRI research examines the impact of combined injury: radiation with other insults, disease, chemical exposures, and other battlefield challenges. Investigations also assess the potential health effects of internal contamination and metal toxicity of militarily relevant metals that may become embedded as shrapnel, such as depleted uranium and tungsten alloys.
  • Biodosimetry—Scientists also seek to develop rapid, high-precision analytical methods that assess radiation exposure doses from clinical samples and thus aid in the triage and medical management of radiological casualties. Researchers are developing dose-assessment assays that test easily obtained samples such as a drop of blood, urine, or hair with transportable equipment. With innovative approaches, they also are improving the accuracy, dose range, ease of use, and speed of classical biodosimetry, which is based on cytogenetic damage.
Representative publications
Below are sample publications from the research program's areas of focus:
  • Biodosimetry
    1. DNA repair-gene expression to identify radiation exposure
      2012—Budworth H, Snijders AM, Marchetti F, Mannion B, Bhatnagar S, Kwoh E, Tan Y, Wang SX, Blakely WF, Coleman M, Peterson L, Wyrobek AJ. DNA repair and cell cycle biomarkers of radiation exposure and inflammation stress in human blood. PLoS One. 7:e48619.
    2. Identifying radiation biomarkers via mass-spectrometry metabolomics
      2012—Johnson CH, Patterson AD, Krausz KW, Kalinich JF, Tyburski JB, Kang DW, Luecke H, Gonzalez FJ, Blakely WF, Idle JR. Radiation Metabolomics. 5. Identification of Urinary Biomarkers of Ionizing Radiation Exposure in Nonhuman Primates by Mass Spectrometry-Based Metabolomics. Radiat Res. 178:328–340.
    3. Enhancing early-phase partial-body exposure assessment
      2011—Blakely WF, Sandgren DJ, Nagy V, Kim S-Y, and Ossetrova NI. Murine partial-body radiation exposure model for biodosimetry studies—Preliminary report. Radiat Meas. 46:898–902.
    4. Optimizing chromosome-aberration studies
      2011—Miura T, Blakely WF. Optimization of calyculin A-induced premature chromosome condensation assay for chromosome aberration studies. Cytometry A. 79(12):1016–22.
    5. Radiation-responsive proteins complement conventional biodosimetry
      2011—Ossetrova NI, Sandgren DJ, Blakely WF. C-reactive protein and serum amyloid A as early-phase and prognostic indicators of acute radiation exposure in nonhuman primate total-body irradiation model. Radiat Meas. 46(9):1019–1024.
    6. Applying the γ-H2AX assay to partial-body radiation exposure
      2011—Redon CE, Nakamura AJ, Gouliaeva K, Rahman A, Blakely WF, Bonner WM. -H2AX, an analysis method for partial-body radiation exposure using γ-H2AX in nonhuman primate lymphocytes. Radiat Meas. 46(9):877–881.
    7. Streamlining the dicentric chromosome assay
      2011—Romm H, Wilkins RC, Coleman CN, Lillis-Hearne PK, Pellmar TC, Livingston GK, Awa AA, Jenkins MS, Yoshida MA, Oestreicher U, Prasanna PG. Biological dosimetry by the triage dicentric chromosome assay: Potential implications for treatment of acute radiation syndrome in radiological mass casualties. Radiat Res. 175(3):397–404.
    8. Dynamic recording of radiation exposure data
      2010—Blakely WF, Madrid JP, Sandgren DJ. Biodosimetry medical recording—Use of the Biodosimetry Assessment Tool. Health Phys. 99 Suppl 5:S184–191.
    9. Discrimination of exposed vs. non-exposed individuals
      2010—Blakely WF, Ossetrova NI, Whitnall MH, Sandgren DJ, Krivokrysenko VI, Shakhov A, Feinstein E. Multiple parameter radiation injury assessment using a nonhuman primate radiation model—Biodosimetry applications. Health Phys. 98(2):153–9.
    10. Early assessment of radiation exposures
      2010—Ossetrova NI, Sandgren DJ, Gallego S, Blakely WF. Combined approach of hematological biomarkers and plasma protein SAA for improvement of radiation dose assessment triage in biodosimetry applications. Health Phys. 98(2):204–8.

  • Countermeasure Development
    1. Cellular therapies
      2012—Singh VK, Christensen J, Fatanmi OO, Gille D, Ducey EJ, Wise SY, Karsunky H, Sedello AK. Myeloid progenitors: A radiation countermeasure that is effective when initiated days after irradiation. Radiat Res. 177:781–791.
    2. Nutraceuticals as radioprotectants
      2012—Kulkarni SS, Cary LH, Gambles K, Hauer-Jensen M, Kumar KS, Ghosh SP (2012) Gamma-tocotrienol, a radiation prophylaxis agent, induces high levels of granulocyte colony-stimulating factor. Int Immunopharmacol. 14:495–503.
      2012—Singh VK, Singh PK, Wise SY, Posarac A, Fatanmi OO (2012) Radioprotective properties of tocopherol succinate against ionizing radiation in mice. J Radiat Res. 2012 Oct 3. [Epub ahead of print].
      2012—Satyamitra M, Ney P, Graves J, Mullaney C, V Srinivasan V. Mechanism of radioprotection by δ-tocotrienol: Pharmacokinetics, pharmacodynamics and modulation of signalling pathways. Br J Radiol. 2012 Jun 6. [Epub ahead of print].
      2012—Singh VK, Wise SY, Singh PK, Ducey EJ, Fatanmi OO, Seed TM. α-Tocopherol succinate and AMD3100-mobilized progenitors mitigate radiation-induced gastrointestinal injury in mice. Exp Hematol. 40:407–417.
    3. Cytokines and growth factors
      2012—Singh VK, Fatanmi OO, Singh PK, Whitnall MH. Role of radiation-induced granulocyte colony-stimulating factor in recovery from whole body gamma-irradiation. Cytokine. 58:406–414..
    4. Dual-use countermeasures for acute and delayed effects
      2011—Miller AC, Cohen S, Stewart M, Rivas R, Lison P. Radioprotection by the histone deacetylase inhibitor phenylbutyrate. Radiat Environ Biophys. 50:585–96.
    5. Animal models of radiation injury
      2011—Moroni M, Lombardini E, Salber R, Kazemzedeh M, Nagy V, Olsen C, Whitnall MH. Hematological changes as prognostic indicators of survival: Similarities between Gottingen minipigs, humans, and other
      large animal models. PLoS ONE. 2011;6:e25210. Epub 2011 Sep 28.
    6. Hematopoietic microenvironment mechanisms
      2012—Li XH, Ha CT, Fu D, Xiao M. REDD1 protects osteoblast cells from gamma radiation-induced premature senescence. PLoS ONE. 2012;7(5): e36604.
    7. Ex-RAD®
      2012—Ghosh SP, Kulkarni S, Perkins MW, Hieber K, Pessu RL, Gambles K, Maniar M, Kao T-C, Seed TM, Kumar KS. Amelioration of radiation-induced hematopoietic and gastrointestinal damage by Ex-RADR in mice. J Radiat Res. doi: 10.1093/jrr/rrs001.
    8. Toll-like receptor agonists
      2012—Krivokrysenko V, Shakhov A, Singh V, Bone F, Kononov Y, Shyshynova i, Cheney A, Maitra R, Purmal A, Whitnall M, Gudkov AV, Feiinstein E. Identification of G-CSF and IL-6 as candidate biomarkers of CBLB502 efficacy as a medical radiation countermeasure. J Pharmacol Exp Ther jpet.112.196071; published ahead of print July 26, 2012, doi:10.1124/jpet.112.196071.
      2012—Singh VK, Ducey EJ, Fatanmi OO, Singh PK, Brown DS, Purmal A, Shakhova VV, Gudkov AV, Feinstein E, Shakhov A. CBLB613: A TLR 2/6 agonist, natural lipopeptide of Mycoplasma arginini, as a novel radiation countermeasure. Radiat Res. 177:628–642.
    9. 5-androstene steroids (first IND for an ARS countermeasure)
      2012—Grace MB, Singh VK, Rhee JG, Jackson WE III, Kao T-C, Whitnall MH. 5-AED enhances survival of irradiated mice in a G-CSF-dependent manner, stimulates innate immune cell function, reduces radiation-induced DNA damage and induces genes that modulate cell cycle progression and apoptosis, J Rad Res. doi: 10.1093/jrr/rrs060.
    10. Effects of radiation quality on countermeasure efficacy
      2012—Cary LH, Ngudiankama BF, Salber RE, Ledney GD, Whitnall MH. Efficacy of radiation countermeasures depends on radiation quality. Radiat Res. 177:663–675.

  • Internal Contamination and Metal Toxicity
    1. Potential for wounds from embedded fragments of radioactive material
      2012—Emond CA, Kalnich JF. Biokinetics of embedded surrogate radiological dispersal device material. Health Phys., 102(2):124–136.
    2. Genetic damage to offspring from parent's exposure to DU
      2010—Miller AC, Stewart M, Rivas R. Preconceptional paternal exposure to depleted uranium: Transmission of genetic damage to offspring. Health Phys., 99(3):371–379.
    3. Assessing toxicity of metals and metal mixtures
      2009—Kane MA, Kasper CE, Kalinich JF. The use of established skeletal muscel cell lines to assess potential toxicity from embedded metal fragments. Toxicol In Vitro., 23(2):356–359.
    4. DNA methylation involvement in DU-induced leukemia
      2009—Miller AC, Stewart M, Rivas R. DNA methylation during depleted uranium-induced leukemia. Biochimie., 91(10):1328–1330.
    5. Health issues associated with newly developed munititions
      2009—Kane MA, Kasper CE, Kalinich JF. Protocol for the assessment of potential health effects from embedded metal fragments. Mil Med., 174(3):265–269.
    6. Determining radioactivity of shrapnel
      2008—Kalinich JF, Vergara VB, Emond CE. Urinary and serum metal levels as indicators of embedded tungsten alloy fragments. Mil Med. 173(8):754–758.
    7. Health effects of internalized tungsten
      2008—Kane MA, Kasper CE, Kalinich JF. The use of established skeletal muscle cell lines to assess potential toxicity from embedded metal fragments. Toxicol In Vitro., 23(2):356–358.
    8. Correlating DU exposure to specific health effects
      2007—Miller AC, McClain D. A review of depleted uranium biological effects: In vitro and in vivo studies. Rev Environ Health, 22(1):75–89.
    9. Shrapnel from tungsten alloy-based munitions
      2005—Kalinich JF, Emond CA, Dalton TK, Mog SR, Coleman GD, Kordell JE, Miller AC, McClain DE. Embedded weapons-grade tungsten alloy shrapnel induces metastatic high-grade rhabdomyosarcomas n F344 rats. Environmental Health Perspectives, 113(6):729–734, 2005.
    10. Pathogenesis of DU-induced leukemia
      2005—Miller AC, Bonait-Pellie C, Merlot R, Michel J, Stewart M, Lison P. Leukemic transformation of hematopoietic cells in mice internally exposed to depleted uranium. Molecular and Cellular Biochemistry, 279(1–2):97–104, 2005.

  • Combined Injury: Radiation with Other Insults
    1. Wounding alters ionizing radiation dose assessment
      2012—Kiang JG, Garrison BR, Burns TM, Zhai M, Dews IC, Ney PH, Cary LH, Fukumoto R, Elliott TB, Ledney GD. Wound trauma alters ionizing radiation dose assessment. Cell Biosci. 2012 Jun 11;2:20. [Epub ahead of print]
    2. Role of sub-mucosal structures in the innate responses to infections
      2012—Gorbunov NV, Garrison BR, Zhai M, McDaniel DP, Ledney GD, Elliott TB, Kiang JG. Autophagy-mediated defense response of mouse mesenchymal stromal cells (MSCs) to challenge with Escherichia coli. In: Protein Interaction/Book 1; ISBN 979-953-307-577-7. Eds.: Cai J. InTech Open Access Publisher. Pages 23–44.
    3. 17-DMAG inhibits radiation-induced p53, improving survival
      2011—Fukumoto R, Kiang JG. Geldanamycin analog 17-DMAG limits apoptosis in human peripheral blood cells by inhibition of p53 activation and its interaction with heat shock protein 90 kDa after ionizing radiation. Radiat Res. 176(3):333–345.
    4. Efficacy of 17-DMAG at reducing hemorrhagic injury
      2011—Kiang JG, Agravante NG, Smith JT, Bowman PD. 17-DMAG diminishes hemorrhage-induced small intestine injury by elevating Bcl-2 protein and inhibiting iNOS pathway, TNF-alpha increase, and caspase-3 activation. Cell & Bioscience 1:21.
    5. Inactivating virus and bacterium with a visible femtosecond laser
      2011—Tsen KT, Tsen SW, Fu Q, Lindsay SM, Li Z, Cope S, Vaiana S, Kiang JG. Studies of inactivation of encephalomyocarditis virus, M13 bacteriophage, and Salmonella typhimurium by using a visible femtosecond laser: Insight into the possible inactivation mechanisms. J Biomed Opt. 16:078003.
    6. Using telemetry to monitor effects of irradiation
      2010—Carrier CA, Elliott TB, Ledney GD. Real-time telemetric monitoring in whole-body (60)Co gamma-photon irradiated rhesus macaques (Macaca mulatta). J Med Primatol. 39:399–407.
    7. D. radiodurans protects against extreme cellular insults caused by ionizing radiation
      2010—Daly MJ, Gaidamakova EK, Matrosova VY, Kiang JG, Fukumoto R, Lee DY, Wehr NB, Viteri GA, Berlett BS, Levine RL. Small-molecule antioxidant proteome-shields in Deinococcus radiodurans. PLoS One. 5(9). pii:e12570.
    8. Paneth cells linked to small-intestine inflammation post-irradiation
      2010—Gorbunov NV, Garrison BR, Kiang JG. Response of crypt paneth cells in the small intestine following total-body gamma-irradiation. Int J Immunopathol Pharmacol. 23:1111–1123.
    9. How combined injury modifies response to irradiation
      2010—Kiang JG, Garrison BR, Gorbunov NV. Radiation combined injury: DNA damage, apoptosis, and autophagy. Adaptive Medicine 2(1):1–10.
    10. Radiation combined injury delays wound-closure
      2010—Kiang JG, Jiao W, Cary LH, Mog SR, Elliott TB, Pellmar TC, Ledney GD. Wound trauma increases radiation-induced mortality by activation of iNOS pathway and elevation of cytokine concentrations and bacterial infection. Radiat Res. 173(3):319–332.

Graduate education in Radiation Biology
A new doctoral program in Radiation Biology has been initiated as a track within the Molecular and Cell Biology (MCB) Program at the Uniformed Services University (USU) in Bethesda, Maryland.

Within this track, students will learn the biology and physics of radiation. Building on a strong and broad basic science background, they will develop the research skills to address the growing scientific needs in radiation biology and develop an understanding of the policy context that is creating the renewed interest in this field.

The radiation biology faculty members are engaged in many exciting areas of research. They are exploring the mechanisms of injury from ionizing radiation in vitro and in vivo animal models, developing new approaches to prevent the life-threatening and health-degrading effects of ionizing radiation, and investigating biomarkers of injury that might be used to assess radiation exposure. The extensive radiation facilities housed at AFRRI can simulate almost any radiation exposure scenario in animal and cellular experiments.

Weekly seminars are presented by AFRRI researchers and other members of the scientific community. View the AFRRI seminar schedule.